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Background: Functional neuroimaging is being used in clinical psychiatry today despite the vigorous objections of
many in the research community over issues of readiness. To date, a systematic examination of the perspectives of
key stakeholders involved in this debate has not yet been attempted. To this fill this gap, we interviewed
investigators who conduct functional neuroimaging studies involving adults with mood disorders, schizophrenia,
obsessive compulsive disorder, and/or attention deficit hyperactivity disorder, providers who offer clinical
neuroimaging services in the open marketplace, and consumers of these services, in order to understand
perspectives underlying different views and practices.
Methods: Semi-structured interviews were conducted over the telephone. Verbal consent was obtained and all
interviews were audio recorded. Interviews of investigators and service providers followed the same interview
guide. A separate set of questions was developed for consumers. All interviews were transcribed and made
software ready. We applied the qualitative methodology of constant comparison to analyze the data, whereby two
researchers independently analyzed the results into textual themes. Coding discrepancies were discussed until
consensus was achieved.
Results: Investigators, service providers, and consumers held many common perspectives about the potential or
actual risks and benefits of functional neuroimaging for mental illness. However, we also found striking divergences.
Service providers focused on the challenges posed by the persistence of symptoms based diagnostic categories,
whereas the limitations of the science in this area was the challenge noted most frequently by investigators. The
majority of consumers stated that their expectations were met.
Conclusion: Our findings point toward a fundamental tension between academic investigators on the one hand,
and commercial service providers and their customers on the other. This scenario poses dangers to the
communities directly involved, and to public trust in science and medicine more generally. We conclude with
recommendations for work that needs to be done to minimize tensions and maximize the potential of
neurotechnology through concerted efforts to respect its limitations while leveraging the strengths, investments,
and hopes of each stakeholder group.Background
Millions of people worldwide are affected by mental dis-
orders such as depression, bipolar disorder, schizophre-
nia, post-traumatic stress disorder and anxiety disorders.
In 2011, the World Health Organization reported that
disorders of mental health are the leading causes of dis-
ability adjusted life years worldwide, accounting for 37%
of healthy years lost from non-communicable diseases* Correspondence: jilles@mail.ubc.ca
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reproduction in any medium, provided the or[1]. A recent report by the World Economic Forum esti-
mated the global cost of mental illness at nearly USD
$2.5 trillion in 2010, with a projected increase to over
USD $6 trillion by 2030 [2]. In the USA, an estimated 11
million American adults (approximately 5% of all adults)
suffer from a seriously disabling mental illness [3]. The
indirect and direct costs associated with mental illness
in the USA have been estimated to be $300 billion annu-
ally [4]. The projected budget for the USA-based Na-
tional Institute of Mental Health (NIMH) – the largest
funder of mental health research in the world – was
$1,479,204,000 [5], with more than two thirds of thatral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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derstanding of the fundamental biology of mental disor-
ders, and the translation of those findings into improved
prevention, diagnosis, treatment selection and monitor-
ing [5]. Research studies employing various neuroimag-
ing technologies consume a significant portion of this
budget. With this as backdrop, our goals here were to:
(1) elucidate the perspectives and beliefs of key stake-
holders on the scientific state of the art in, and potential
for the clinical translation of, neuroimaging and mental
health; and (2) to offer guidance based on the results for
closing knowledge gaps, bridging hopes and tensions,
and translating knowledge into action.
Our work is motivated by the central role that structural
and functional neuroimaging have played in the search for
a biological foundation for psychiatry. In 1976, Johnstone
and colleagues demonstrated that patients with schizo-
phrenia had enlarged cerebral ventricles [6], delineating
for the first time the neural correlates of a psychiatric ill-
ness. In more recent years, neuroimaging researchers have
used structural as well as functional signals to explore and
discover the biological bases of mental illness.
A major focus of contemporary neuroimaging research is
the identification of imaging biomarkers. Radioligands that
bind to neurotransmitter receptors and transporters have
been used to measure target occupancy for use in proof of
mechanism studies, and to determine required dosage for
new antipsychotic drugs [7] and anti-depressants [8].
Multivoxel pattern analysis has been used to develop im-
aging biomarkers for the detection of prodromal schizo-
phrenia [9], and diffusion tensor imaging has been applied
to the early detection of first episode psychosis in schizo-
phrenia [10] and ASD in children [11].
Imaging genetics has also offered significant insights,
allowing researchers to characterize the molecular path-
ways of neurological and mental health disorders [12].
Researchers working in this area have focused on three
types of variants: functional variants with a known
neurochemical effect [13,14]; common variants which
are known to make a small or medium sized contribu-
tion to disease risk [15,16]; and rare variants which are
known to make a large contribution to disease risk
[17,18]. Substantial progress has also been made using
genome-wide association studies (GWAS) that identify
risk variants for psychiatric diseases in the absence of
knowledge concerning their function. For example, sev-
eral single-nucleotide polymorphisms on genes coding
for subunits of the GABA-A receptor have been associ-
ated with bipolar disorder using GWAS [19].
Finally, imagers have begun to focus on simple behav-
ioural states and traits associated with particular mental
disorders. This research strategy is based on the supposition
that it is easier to reliably identify the neural correlates of
simple behavioural states and traits than the complexphenotypes typical of most mental disorders. This strategy
has had success. For example, researchers working with pa-
tients with schizophrenia have used this approach to iden-
tify the neural activation patterns associated with verbal
hallucinations by asking patients suffering from auditory
verbal hallucinations to report the on- and offset of the
voices [20-22].
Despite the importance of these breakthroughs, the overall
progress in diagnostic and prognostic imaging biomarkers
of mental disorders has been slower than anticipated.
According to many experts in the field, diagnostic and prog-
nostic imaging biomarkers – genetic or otherwise – remain
a long way from clinical application [23-25].
Academic viewpoints notwithstanding, early adopters
offer neuroimaging to mental health consumers on the open
market in the USA and Canada. The homepage on the web-
site of a prominent North American provider states:
[We are] highly effective at helping people of all ages
have better brains and better lives. Our success rate is
very high by using detailed evaluations and brain
SPECT [single photon emission tomography] imaging
to better target treatment [26].
Their website provides detailed information concerning
how brain scans can help persons suffering from a variety
of disorders. For example, the website says SPECT can
specifically reach people with anxiety and depression by
helping them to: evaluate whether or not the person has
anxiety or depression, determine the type of anxiety or de-
pression to inform treatment decisions, determine if treat-
ment is effective, assess for the presence of co-occurring
conditions, reduce emotional pain and stigma by demon-
strating that symptoms and behaviors are not imaginary,
increase treatment compliance, and gain a better under-
standing of mental illness [26].
Similar potential benefits – related to diagnosis, treat-
ment selection, treatment monitoring, de-stigmatization,
compliance, and understanding – are noted for persons
with attention disorders, addictions, autism spectrum,
behavioural problems, brain injury, marital conflict,
memory issues, and weight issues [26]. To our know-
ledge, neither primary nor secondary insurance coverage
is available for these services in any health system; cus-
tomers pay out-of-pocket. The clinic quoted above offers
customers “CareCredit” with 0% financing to enable pro-
spective consumers to purchase neuroimaging services
without delay.
The practice has drawn heated criticism from main-
stream psychiatry. Although papers on the use of SPECT
scans in psychiatry [27-32] have been published and pro-
viders claim that the work is “based on hundreds of texts
and scientific articles” [33], critics contend that the pub-
lications do not support the use of SPECT imaging in
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critics cite the 2006 Practice Guidelines issued by the
American Psychiatric Association [35] which state that:
… the clinical utility of neuroimaging techniques for
planning of individualized treatment has not yet been
shown. Further research is needed to demonstrate a
clinical role for structural and functional neuroimaging
in establishing psychiatric diagnoses, monitoring illness
progression, and predicting prognoses [36].
A major review of neuroimaging in psychiatry pub-
lished in the January 2012 issue of Neuron suggests that
the APA’s position remains current. According to the au-
thor, neuroimaging
“… so far has not yielded clinically relevant
biomarkers for [disease, prognosis, or treatment of]
mental disorders” [23].
Objections to the direct-to-consumer approach, how-
ever, are not merely academic. Critics charge that the
for-profit sector is jeopardizing public trust in the field
and putting patients at risk. These charges are summa-
rized in a 2010 letter published in the American Journal
of Psychiatry:
There are several dangers to patients that can accrue
from [this] approach: 1) patients (including children) are
administered a radioactive isotope without sound clinical
rationale; 2) patients pursue treatments contingent upon
an interpretation of a SPECT image that lacks empirical
support; and 3) based on a presumed diagnosis…,
patients are guided toward treatment that may detract
them from clinically sound treatments [34].
Although the battle lines in this acrimonious debate
seem to be drawn, it is important to note that – to date – a
systematic examination of the perspectives of key stake-
holders involved has not yet been attempted. To this fill
this void, we interviewed neuroimaging researchers, pro-
viders of neuroimaging services, and consumers of these
services. Our goals were to: (1) elucidate the perspectives
of researchers on the state of the art in translational neuro-
imaging research; (2) understand the opinions of providers
currently offering functional neuroimaging clinically; and
(3) explore the expectations and experiences of consumers
of these services. From the triangulation of these findings,
we offer guidance for translating of the resulting know-
ledge into action.
Methods
This study was reviewed and approved by the behav-
ioural research ethics board at the University of BritishColumbia. Informed consent was obtained from all par-
ticipants. We conducted semi-structured interviews
with: 1) investigators who conduct functional neuroim-
aging studies involving adults with mood disorders,
schizophrenia, obsessive compulsive disorder, and/or at-
tention deficit hyperactivity disorder; 2) providers who
conduct or order functional neuroimaging examinations
clinically in this population; and 3) consumers who, in
order to obtain information related to mental, psycho-
logical, or emotional health, have purchased brain scans
or have had brains scans purchased for them.
Recruitment
Investigators
Academic investigators involved in functional neuroim-
aging research related to mood disorders (bipolar and
unipolar disorders), schizophrenia, obsessive compulsive
disorder (OCD), and/or attention deficit disorder
(ADD)/attention deficit hyperactivity disorder (ADHD)
who were fluent English speakers were identified using a
combination of purposive and snowball sampling
methods. We conducted two targeted searches of the
USA-based National Institutes of Health (NIH) Re-
PORTER database. The first search involved the search
terms: “SBIR/STTR” AND “Functional neuroimaging”
AND “Mental Health.” The second search utilized the
search terms: “RO1 equivalents, DP2, RO1, R23, R29,
R37” AND “functional neuroimaging” AND “mental
health.” We also conducted a parallel search of the
Canadian Institutes of Health Research (CIHR) funded
research database using the search terms: (any of the
phrases) mood, bipolar, anxiety, schizophrenia AND
(any of the phrases) imaging. An initial set of prospect-
ive participants was created from the search returns.
Additional participants were identified via snowball
sampling.
Service providers
Clinicians working at clinics that offer clinical neuroim-
aging services related to mood disorders (bipolar and
unipolar disorders), schizophrenia, OCD, and ADD/
ADHD were also identified using purposive and snow-
ball sampling. We created an initial set of potential par-
ticipants by searching the Internet for clinicians who
satisfied the above eligibility criteria. We then used
snowball sampling to identify additional eligible partici-
pants not identified in the initial search.
Consumers
Men and women age 19–75 who, in order to obtain in-
formation related to mental, psychological, or emotional
health, had purchased brain scans or had had brain
scans purchased for them, who had the capacity to
understand the nature of the study, who could provide
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were identified through one of four recruitment strat-
egies: (1) Google ad linked to key words “brain MRI im-
aging,” “SPECT,” MRI scan of the head,” “brain scan
results,” brain MRI scan,” and “cost of brain MRI scan,”
with a one-line description of the study, and a link to a
recruitment poster posted on the homepage of the au-
thors’ organizational website; (2) Craigslist ad (San
Francisco) with a one-line description of the study, and
a link to the homepage of the authors’ organizational
website; (3) ads on five top rated mental health websites
as rated by the analytic site ‘compete.com’ at the time of
recruitment, with a one-line description of the study,
and the link to the recruitment poster; and (4) poster on
the website or in the newsletter of service providers.
Data collection and analysis
Data for this study constituted open answers to questions
posed during semi-structured interviews designed to take
approximately 30 min. All interviews were conducted over
the telephone. Verbal consent was obtained and all inter-
views were audio-recorded. Confidentiality was achieved
by assigning an alphanumeric identifier to each participant
and immediately disassociating names from responses.
Interviews of investigators and service providers followed
the same interview guide. Questions focused on a range of
salient issues including the focus of their research on the
continuum from basic research to clinical application, chal-
lenges, and the future of functional neuroimaging research.
The questions are summarized in Table 1. This table also
summarizes the parallel but separate set of questions devel-
oped for consumers.
Analysis
All interviews were transcribed and made software ready
(NVivo 9, QSR International). We applied the qualitative
methodology of constant comparison to analyze the
data, whereby two researchers independently examined
the transcriptions. This involved segmenting raw data,
labelling and coding, while searching for patterns of
intersection. Major themes and their constituent sub-
themes were counted only once even if they appeared
more than once in a given transcript to provide control
for individual biases. We applied an interpretative andTable 1 Summary of interview questions
Investigators and service providers
• Location of research on a continuum from basic research to clinical application
• Focus of efforts
• Challenges faced in research and practice
• Barriers to clinical translation of functional neuroimaging
• Necessity of prospective clinical trials
• Risks and benefits to patient-participantsiterative process, critically analyzing and conceptualizing
the results into textual themes [37-41]. Coding discrep-
ancies were highlighted and discussed between two
trained coders to achieve consensus. Dominant themes
and subthemes emerged from the triangulation of all as-
pects of the analysis. Quotations presented in Results
below were chosen for their representativeness of the
phenomena identified and described.
Results
Tables 2, 3 and 4 shows the full range of themes and
subthemes derived from the analysis, and their distribu-
tion and frequency of occurrence across interviews with
investigators, providers, and consumers. We present
prominent themes as they emerged from the coding
strategy. Full details of the constituent subthemes are
shown in the tables. We provide illustrative quotations
in the text below to enrich the data.
Investigators
Altogether thirty-six investigators were invited by email to
participate. Twenty-two investigators completed the study,
at which point recruitment was terminated due to theoret-
ical saturation [39,40] of the data. Twenty of the twenty-
two investigators viewed their work in at least partly trans-
lational terms on the spectrum from bench research to
bedside care, with two describing their work in purely
basic or non-translational terms. The investigators in the
former group located their work at various, sometimes
overlapping stages on the translational pathway. Eighteen
of these investigators viewed their work as preparatory to
clinical studies proper – what we called “developing tools
for clinical translation.” Ten of the investigators reported
that they were participating in clinical studies.
Six major themes emerged as determined by their preva-
lence in the discourse of the participants interviewed
(Table 2):
(1) Goals: Improving and facilitating treatment choice for
people with mental illness emerged as the dominant
code under the theme of goals. For example,
The current purpose of my work is to understand
brain mechanisms of how people get better fromConsumers
• Sources of information about functional neuroimaging
• Features of interest in about brain scans
• Motivation to pursue a brain scan
• Knowledge gained
• Impact of experience
• Expectations and level of satisfaction with experience and brain scan
Table 2 Interviews with investigators
Coded themes/Subthemes Number of interviews in
which coded themes and
subthemes occur/total N
Coded themes/Subthemes Number of interviews in
which coded themes and
subthemes occur/total N
(N = 28) (N = 28)
Goals of research Risks to participants
Treatment choice 9 Noise, claustrophobia 11
Prediction 7 Incidental findings 9
Monitoring 5 False hope for treatment 8
Treatment 4 Distrust of science or medicine 3
Diagnosis 3 Inaccurate diagnosis 6
Pre-surgical planning 3 Increased stigma 5
Defining populations 1 Negative self-understanding 4
Challenges Distrust of science or medicine 3
Scientific challenges 12 Breach of confidentiality 2
Funding challenges 8 Discrimination (e.g., insurance) 2
Technical limitations 5 None (explicitly) 3
Heterogeneous protocols 1 Future of neuroimaging
Participant recruitment 4 Clinical trials needed 16
Ethics review itself 2 Clinical trials not needed 1
Balancing research with care 2 Larger samples 13
Obtaining informed consent 1 Multi site trials 12
Lack of creativity in the field 2 Controlled studies 7
Potential benefits Blinded trials 5
Improved care 9 Randomized trials 5
Better understanding illness 6 Longitudinal studies 2
Reduced stigma 5 Add-on studies 2
Improved self-attitude 1 Standardized imaging protocols 6
New knowledge 2 Different models of disease 2
None (explicitly) 2 Drug trials 2
Clinical Uptake
Demand from clinicians 1
Science not ready 11
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this. One is to create personalized treatment
algorithms. That is to better refer people to treatments
that they would likely benefit from. And two, to help to
refine the treatments that exist, or create treatments
that more effectively target brain mechanisms
associated with disease which are not targeted in
current treatments (NII007).
(2) Challenges: Investigators identified a broad range of
challenges associated with research in the area of
neuroimaging for mental health disorders.
Limitations related to the state of the science was
the most prominent code. For example,
I just don’t think that the science is there yet … (NII008).(3) Benefits: Improved care was the code that emerged
prominently under the theme of benefits. Emergent
codes also highlighted the importance of
possibilities for a better understanding of mental
illness and de-stigmatization. For example,
… Neuroimaging has] had an important contribution
to kind of the sociology of how we think about mental
illness. (NII05).
(4) Risks: Noise, claustrophobia, and radiation were the
risks that emerged prominently in the data. Risks of
incidental findings, distrust of medicine, discrimination,
and breaches of confidentiality were also coded.
(5) Future of functional neuroimaging: The need for
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example,
We have been tremendously, tremendously limited by
small sample sizes, by particular oddities of particular
populations or treatments, and lack of an
understanding of what a placebo does, for example,
relevant to a medication. Or even what a real clinical
choice might be that a person—a provider with a
patient might be faced in the clinic, and aligning that
with how we do our research. So putting functional
neuroimaging with actual, properly done clinical trials
helps merge those sets of interests and challenges
(NII008).
(6) Clinical uptake: The immaturity of imaging science
in the context of mental health and the consequent
need for caution with respect to clinical application,
characterized the dominant response to the
question about readiness of the technology for the
psychiatry clinic. For example,
… imaging is not as strong for defining diseases as the
DSM criteria are… it’s not as accurate as standard
behavioural interviews and scales for diagnostic
classification… I just think we’re not doing it because
it’s not a responsible thing to do… (NII012).ble 3 Interviews with service providers
ded themes/Sub-themes Number of interviews in









Lack of creativity 1
Professional censure 1
Lack of clinician-researchers 1
Limited clinical knowledge 1
Symptom-based diagnosis 2
Distrust of the Academy 1
Limited training 1
Lack of clinical interest 1
Insurance 1Service providers
We identified eleven eligible participants who satisfied the
eligibility criteria for the study. Five participated. These
participants saw their work in clinical terms, with four of
the five providers stating that they were actively using
functional neuroimaging in their clinical practice. One
provider also noted involvement in clinical research.
The major themes coded from this group were similar to
those emerging in the interviews with investigators (Table 3):
(1) Goals: Treatment choice was the dominant code in
the discourse about goals. The use of functional
neuroimaging for diagnostic purposes was also
prominent in the interviews.
(2) Challenges: Limitations of symptom-based
diagnostic categories was the most frequent code
concerning the challenges associated with the use
of neuroimaging in clinical psychiatry. For example,
[W]hat’s going on in the country is that there’s a very
significant limitation to the current diagnostic coding
system. It’s really, to be completely plain about it,
based on appearances, because really all we’ve had for
years is appearances. Now, I mean there are some
diagnostic codes in there that having something to do
with genetics… [T]he bottom line is, human beings in
the office are labelled by how they behave, and by whatCoded themes/Sub-themes Number of interviews in
which coded themes and





Increased family support 1
Improved self-attitude 1
Risks to patients
False hope for treatment 2
Cost 1
Misuse of technology 2
Patient self-understanding 1
Future of neuroimaging
Clinical trials needed 1
Clinical trials not needed 1
Controlled studies 1
Standardized imaging protocols 1
Rationale for clinical use
Demand from other clinicians 1
Scientific promise 1
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to what’s actually necessarily going on. And so imaging’s
a very important point. If you’re using—if you’re finding
that using the current diagnostic naming system to drive
your treatments is limited and insufficient, it’s going to
be natural to seek further information with more brain
function evidence (NII026).Distrust and professional censure, limited training
opportunities, lack of creativity in the field, and a
shortage of medically-trained neuroimaging
researchers were also coded.
(3) Benefits: Benefits related to the possibilities for
improved care and the destigmatization of mental
illness were the primary codes related to benefits in
the interviews of providers.
(4) Risks: False hope and the misuse of technology
were the most prominent risk codes. For example,
The risk of the test is misusing the test. The risk is
telling—giving people false hope, which I—which I
never do. I think it’s very important to explain to
patients as carefully as possible, like, what the
benefits, what the risk –, what I can do with the
information, what I can’t do (NII032).
(5) Future of neuroimaging: Coding highlighted an
emphasis on guidelines and standardization but not
necessarily on clinical trials. For example,
[W]hat do we need to make it more possible to have
imaging really a standard part of psychiatric
medicine? …we need standards that we don’t have.
Standard ways to do the procedure, to interpret the
procedure, and a standard body of literature that
everybody can refer to (NII022).
(6) Clinical uptake: When asked why functional
neuroimaging was limited clinically in the context
of mental illness, providers cited a number of
factors including lack of interest. The following
quotation is illustrative:
There’s not enough people who are doing it that are
excited about it. It’s not that it’s not useful. (NII022).
Consumers
Seventy-seven individuals responded to the recruitment ads
for the consumer arm of the study. Most of these individuals
learned about the study through posters in the offices, news-
letters, or websites of service providers. The rest accessed in-
formation about the study via our Google Ad or web-based
mental health fora. There were no respondents to theadvertisement on Craigslist. Of the seventy-seven individuals
who responded initially, six were ineligible and forty-three
did not respond to follow up. Twenty-eight respondents
constituted the final sample, yielding a response rate of 44%.
All participants completed a demographic survey be-
fore the interviews began. The majority of participants
were Caucasian (27 of 28), and one was African Ameri-
can. A majority of the participants were female (17 of
28) Almost sixty percent of the participants reported in-
comes over $75K USD, and forty-three percent of re-
spondents reported that they held a graduate degree.
Seven major themes were coded from the interviews
with consumers (Table 4):
(1) Sources of information about brain imaging: Popular
media (i.e., Internet, television, popular books)
emerged as the primary source of information.
(2) Motivation: Coding highlighted consumers’ desire
for a clear and objective diagnosis as the primary
motivation for pursuing neuroimaging in the open
marketplace. For example,
… I thought that with certainty, the kind of certainty
you can get with a picture, maybe that would help
us… (C007).… brain imaging would get us a better assessment, a
more complete assessment than the nonsense I was
getting here (C024).Hope for better treatment and distrust of
traditional psychiatry also emerged prominently in
the coded interviews.
(3) Concerns: Little in the data suggested concerns
about neuroimaging. The few coded units for this
theme related to radiation.
(4) Results received: New diagnosis, confirmation of an
existing diagnosis, or a new secondary diagnosis
dominated codes for results received. For example,
[T]hey said I had kind of an ADD process where, you
know, when I’m concentrating, especially on, you know,
something that’s relatively mundane, there’s a decrease
of function in the front part of my brain, so that it
lends itself to having more difficulty with staying on
task with boring things (C014).
(5–7) Impact, evaluation and experience: Consumers
identified many types of impact from the
clinical consultation they received. Changes in
treatment and physical or psychological relief
dominated the codes for this theme. For
example,
Table 4 Interviews with consumers
Coded themes/Subthemes Number of interviews in
which coded themes and
subthemes occur/total N
Coded themes/Subthemes Number of interviews in
which coded themes and
subthemes occur/ total N
(N = 28) (N = 28)
Source of information Impact of scan
Popular media 20 Change of treatment 18
Professional sources 5 Better treatment 10
Word of mouth 4 Relief or quality of life 18
Motivation to seek scan Better understanding of disorder 14
Objective diagnosis 23 Improved self-attitude 13
Better understanding 14 Sense of empowerment 11
Better treatment 11 Acceptance by others 11
Skepticism - psychiatry 11 Increased hope 10
Undiagnosed concerns 8 Belief in diagnosis 6
No other options 5 Decreased stigma 5
Legal reason 2 Decreased hope 4
Concerns about the scan None (explicitly) 2
Cost 13 Worse self-attitude 1
Radiation 6 No change in treatment 1
Meaningfulness 4 Decreased compliance 1
Unexpected bad news 3 Evaluation
Lack of insurance 3 Expectations fully met 22
Claustrophobia 2 Would do it again 22
Uninformative findings 2 Worth the cost 8
Confidentiality 1 Expectations partly met 5
Change in therapy 1 Would not do it again 1
Results received Overall experience
New primary diagnosis 12 Positive 25
Confirmation of existing diagnosis 11 Negative 3
New secondary diagnosis 11
Exclusion of a suspected diagnosis 2
None (explicitly) 2
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crazy (C039).[T]his made me feel more in control of my own life.
And that’s a really good feeling to have. That’s
definitely worth thirty-five hundred dollars (C023).
Better understanding of mental illness, improved self-
attitude, a sense of empowerment, and increased hope
were also coded frequently. We coded a few instances of
negative discourse regarding decreased hope, impeded
compliance with treatment, and a worsened attitude to-
ward the self.
Discussion
To map the current translational landscape of functional
neuroimaging for mental illness, we interviewedinvestigators who are conducting functional neuroimag-
ing studies involving adults with mood disorders, anxiety
disorders, or schizophrenia, providers who are applying
functional neuroimaging clinically in this population,
and consumers of these services.
We found six to seven major emergent themes in each
group, and among them convergence in perspectives
across the three groups in some domains. Investigators,
service providers, and consumers held common perspec-
tives about the potential or actual risks and benefits of
functional neuroimaging for mental illness. All three
groups pointed to improved care as a major goal of
functional neuroimaging in this context and shared simi-
lar goals for improved diagnosis, treatment choice, and
compliance. All three groups also discussed cost and ac-
cess, the importance of mitigating false hope, and the
meaningfulness of findings.
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perspectives between participants in the three groups are
striking if not unexpected. When asked about the chal-
lenges they face in their work, the concerns of investigators
and service providers overlapped to a limited extent. Over-
all, the persistence of symptoms based diagnostic categories
was the challenge noted most frequently by service pro-
viders, whereas the limitations of the science in this area
was the challenge noted most frequently by investigators.
Consumers’ perspectives on their own experiences with
brain scans sit uneasily against the backdrop of these pro-
fessional disagreements. Though some consumers did ex-
press concerns about the validity or efficacy of functional
neuroimaging in this context, consumers’ evaluation of
the service they received was positive: the majority stated
their expectations were met. That said, only a subset
stated they would do it again or recommend it to others
given the $3500-4000 USD cost.
In sum, the evidence paints a conflicted picture. Aca-
demic investigators are skeptical about the clinical appli-
cation of neuroimaging in the context of mental health
given the current state of the science. By contrast, com-
mercial service providers are enthusiastic, based on their
clinical experience for the most part. Consumers, finally,
are caught in the middle. All told, this scenario poses
dangers to everyone: academic investigators risk missing
the opportunity to shape the uptake of this emerging
technology in the marketplace; commercial service pro-
viders, who already face significant resistance, risk a
backlash from the academic community; and consumers
themselves may come to distrust both parties.
Indeed, such open antagonism between the academic
and commercial communities undermines trust in sci-
ence and medicine and, ultimately, does a disservice to
the public. As Ellison writes in her recent book Buzz
(2010), we are
… drowning in data and confused by endless
controversies (p. 149).
Professional disputes may be newsworthy but they are
often unproductive distractions as well.
It is important to note the limitations of this study.
The data reflect the perspectives of a closed and limited
set of investigators, providers, and consumers. The ser-
vice provider pool is particularly small, and the use of
snowball sampling to identify investigators and service
providers may have biased the results. Consumers who
self-selected to participate may have been particularly
satisfied with services received. The data are also limited
in terms of the overall ethnic and cultural diversity of
participants. Finally, some degree of coder bias is inevit-
able when working with qualitative data, even in the face
of systematic analyses and consensus.Study limitations notwithstanding, these findings shed
light on the current translational landscape of functional
neuroimaging for mental illness. It is clear that much work
needs to be done to both minimize existing tensions and
to maximize the potential of this exciting new technology.
With these goals in mind, we draw upon the data to offer
the following recommendations for future action:
Create a mental health neuroimaging consortium
We recommend the creation of a consortium for func-
tional neuroimaging in mental health, that builds on the
strengths of existing shared databases such as BRAINNet,
OpenfMRI, BrainMap, meta-analytic methods such as the
ALE and ES-SDM, and others such as the Alzheimer's Dis-
ease Neuroimaging Initiative (ADNI). Members of the
consortium would follow standardized protocols for data
acquisition, data analysis, and repositories for data mining
and sharing. It should be co-funded by major government
health agencies that have mental health at the focus of
their mandate, and properly include a component dedi-
cated to cultural representation. The consortium should
focus initially on biomarkers for treatment selection and
monitoring in a discrete number of disorders. Given ad-
vances particularly in the area of schizophrenia [23], this
would be a good first target. The consortium should part-
ner with the pharmaceutical industry to conduct large
clinical trials akin to drug and cancer trials [25]. These
should be unencumbered and monitored by an independ-
ent scientific board. The work should be conducted within
an open and transparent framework of collaboration that
destigmatizes academy-industry research and mitigates
suspicion of bias.
Conduct retrospective studies of extant databases
We recommend retrospective studies of extant commer-
cial image databases. The for-profit imaging sector boasts
vast image databases but, to date, they remain an un-
tapped resource. Studies of these databases could be made
possible via open competition for research contracts and
paid for in part by the commercial sector and carried out
in partnership with academia. These studies would need
to undergo continuous review by a scientific advisory
board that has equal membership from both sectors.
Rigorous methods and effective dissemination strategies
anchored in pre-engagement ethics agreements should be
central requirements of potential proposals.
Build on commercial reach and know-how
The academic neuroimaging community, academic insti-
tutions, research sponsors, and others should harness
the know-how and reach of the commercial marketing
machine to raise awareness and improve education of
mental health disorders. The visibility of the commercial
sector is indisputable. With careful management, there
Anderson et al. BMC Psychiatry 2013, 13:208 Page 10 of 11
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Conclusion
Our findings point toward a fundamental tension be-
tween academic investigators on the one hand, and com-
mercial service providers and their customers on the
other. This scenario poses dangers to the communities
directly involved, and to public trust in science and
medicine more generally. Much work needs to be done
to mitigate these dangers and maximize the potential of
exciting new technology. With a focus on the patient
and the collective strengths of both the research and ser-
vice provider communities, constructive steps can be
successfully undertaken to achieve these parallel goals.
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